StockDuty ← Dashboard Jul 31, 2026 05:33 PM ET
SignalCorporate

Castle Biosciences raises 2026 revenue guidance to $365M-$375M as TissueCypher volume trends toward 50%-52% growth

Castle Biosciences raises 2026 revenue guidance to $365M-$375M as TissueCypher volume trends toward 50%-52% growth

What changed
Castle Biosciences raises 2026 revenue guidance to $365M-$375M as TissueCypher volume trends toward 50%-52% growth
Why it matters
Castle Biosciences raises 2026 revenue guidance to $365M-$375M as TissueCypher volume trends toward 50%-52% growth — impact context not separately stored; see What changed.
Sources
eodhd
Related signals
FITCH AFFIRMS CHINA CREDIT RATING AT 'A' →FITCH ISSUES NEW STATEMENT AND OUTLOOK ON U.S . CREDIT RATING DEBT WARNING IN FIRST PARAGRAPH . →$FMX →